Optimising malignant melanoma management in Europe
EUMelaReg collects health information to improve care and treatment for patients with skin cancer
Sustaining and fostering collaboration between academia and industry
for the collection of baseline, treatment and outcome data of representative samples of malignant melanoma patients of major European countries.
Building the largest and quickest melanoma registry in the world
EUMelaReg collects real-world data on melanoma patients throughout Europe and integrates them in a data warehouse.

Adjuvant use of Pembrolizumab for stage III melanoma in a real-world setting in Europe

We are delighted to announce that our multi-country real-world study “Adjuvant use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe” has been accepted by the journal Cancers. The study, using data from EUMelaReg (European Melanoma Registry), investigates the use of pembrolizumab as an adjuvant treatment for stage III melanoma. To investigate the treatment and outcome for adult patients with stage III melanoma with lymph node involvement who had a complete resection and received adjuvant treatment with pembrolizumab. The main objectives were to describe the demographic and clinical characteristics of the enrolled patients, as well as the time on adjuvant pembrolizumab treatment (TOT), real-world recurrence-free survival (RFS), and distant metastasis-free survival (DMFS) from the start of adjuvant pembrolizumab treatment. Secondary objectives were time to next treatment (TTNT) after adjuvant use of pembrolizumab, next-line therapy in stage III and unresectable stage IV melanoma, and overall survival (OS) from initiation of pembrolizumab. The results of this study provide insights into the real-world use of pembrolizumab as adjuvant therapy for melanoma in Europe.